Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. BIOGF.PINK

Biocartis Group NV (BIOGF PINK) stock market data APIs

$0.66 0(0%) as of July 25, 2024
Price chart is built with Anychart

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Biocartis Group NV Financial Data Overview

0.66
0.66
-
0.66
0.66
0.66-0.66
65 406 K
93 916 K
60 822 K
-0.339
1.323
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BIOGF',
Type: 'Common Stock',
Name: 'Biocartis Group NV',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00ZXQ9WR9',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Diagnostics & Research',
HomeCategory: NULL,
IsDelisted: false,
}

Biocartis Group NV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 60 822 K
  • EBITDA -37 015 000
  • Earnings Per Share -0.98
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Biocartis Group NV Earnings via APIs

  • Latest Release 2020-12-31
  • EPS/Forecast 0

Get Biocartis Group NV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Biocartis Group NV latest news via APIs

Press release Biocartis Group NV: Disclosure of transparency notification

Biocartis NV PRESS RELEASE - REGULATED INFORMATION 3 March 2023, 17:40 CET Disclosure of transparency notification Mechelen, Belgium, 3 March 2023 – Biocartis Group NV (the ‘Company’ or ‘B...
  • BIOCARTIS GROUP NV
  • CREDIT SUISSE
  • EURONEXT BRUSSELS
  • MOLECULAR DIAGNOSTICS
  • NOTIFICATION REQUIREMENT
  • VOTING RIGHTS

Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test

  • BIOCARTIS GROUP NV
  • COLORECTAL CANCERS
  • DNA MISMATCH REPAIR
  • EURONEXT BRUSSELS
  • FDA
  • LYNCH SYNDROME
  • MICROSATELLITE INSTABILITY
  • MOLECULAR DIAGNOSTICS
  • MSI
Do you have any questions?
support@eodhistoricaldata.com